" class="no-js "lang="en-US"> Allergan - Medtech Alert
Monday, September 08, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Allergan | Pharmtech Focus

Allergan

About Allergan

Allergan

Allergan is now part of AbbVie.

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.

For more information about AbbVie, please visit us at www.abbvie.com. Follow @AbbVie on LinkedIn for future updates.

Related Story

Drug Development

 Now Available Over the Counter

Now Available Over the Counter, LASTACAFT ® Provides Eye Allergy Itch Relief in Minutes that Lasts Through 16 Hours

March 16 2022

Allergan, an AbbVie (NYSE: ABBV) company, today announced that LASTACAFT ® (alcaftadine ophthalmic solution 0.25%) is […]

News

 Allergan to Share New Data at ARVO 2021 | Pharmtech Focus

Allergan to Share New Data at ARVO 2021

April 27 2021

Allergan, an AbbVie (NYSE: ABBV) company, today announced that it will present new data, including […]